Review Article
Ingibjörg Gunnarsdottir1* and Lisbeth Dahl2
1Unit for Nutrition Research, University of Iceland and Landspitali The National University Hospital of Iceland, Reykjavik, Iceland; 2National Institute of Nutrition and Seafood Research (NIFES), Oslo, Norway
Abstract
The present literature review is a part of the NNR5 project with the aim of reviewing and updating the scientific basis of the 4th edition of the Nordic Nutrition Recommendations (NNR) issued in 2004. The main objective of the review is to assess the influence of different intakes of iodine at different life stages (infants, children, adolescents, adults, elderly, and during pregnancy and lactation) in order to estimate the requirement for adequate growth, development, and maintenance of health. The literature search resulted in 1,504 abstracts. Out of those, 168 papers were identified as potentially relevant. Full paper selection resulted in 40 papers that were quality assessed (A, B, or C). The grade of evidence was classified as convincing, probable, suggestive, and no conclusion. We found suggestive evidence for improved maternal iodine status and thyroid function by iodine supplementation during pregnancy. Suggestive evidence was found for the relationship between improved thyroid function (used as an indicator of iodine status) during pregnancy and cognitive function in the offspring up to 18 months of age. Moderately to severely iodine-deficient children will probably benefit from iodine supplementation or improved iodine status in order to improve their cognitive function, while only one study showed improved cognitive function following iodine supplementation in children from a mildly iodine-deficient area (no conclusion). No conclusions can be drawn related to other outcomes included in our review. There are no new data supporting changes in dietary reference values for children or adults. The rationale for increasing the dietary reference values for pregnant and lactating women in the NNR5 needs to be discussed in a broader perspective, taking iodine status of pregnant women in the Nordic countries into account.
Keywords: iodine; nutritional status; nutritional requirements; nutrition policy
Received: 3 April 2012; Revised: 7 September 2012; Accepted: 18 September 2012; Published: 9 October 2012
Food & Nutrition Research 2012. © 2012 Ingibjörg Gunnarsdottir and Lisbeth Dahl. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation: Food & Nutrition Research 2012. 56: 19731 - http://dx.doi.org/10.3402/fnr.v56i0.19731
Iodine is an essential component of the thyroid hormones, thyroxine (T4) and triiodothyronine (T3), necessary for normal growth, development, and metabolism during pregnancy, infancy and throughout life (1–3). When the physiological requirements for iodine are not met, a series of functional and developmental abnormalities occur, including thyroid function abnormalities. Severe iodine deficiency results in hypothyroidism, endemic goiter and cretinism, endemic mental retardation, decreased fertility, increased prenatal death, and infant mortality (1– 4). High iodine intake may also cause disturbances in the thyroid function (1, 3, 4).
In the 4th edition of the Nordic Nutrition Recommendation (NNR) (4) issued in 2004, the recommended daily intake (RDI) of iodine was kept unchanged from the 3rd edition (1996). RDI was set to 90 µg/day for children aged 2–5 years, 120 µg/day for children aged 6–9 years, and 150 µg/day for children from 10 years of age, adolescents, and adults. The RDI for iodine presented in NNR 2004 for children, adolescents, and adults is in line with current reference values from different countries and organizations (1, 5). In the 4th edition of NNR, an extra 25 µg/day was recommended during pregnancy (RDI set to 175 µg/day) and extra 50 µg/day during lactation (RDI set to 200 µg/day) to provide sufficient iodine in the breast milk (NNR 2004). These reference values were lower than the reference values of 200 µg/day during pregnancy and 250 µg/day during lactation presented by FAO/WHO in 2005 (1). Furthermore, the WHO/UNICEF/ICCIDD recently increased reference values for pregnant women from 200 to 250 µg/day (6).
The recommended indicator for measuring iodine status is based on the population median urinary iodine concentration (UIC) and iodine intake is regarded as adequate when the UIC is 100–199 µg/L (2, 3). Population iodine sufficiency during pregnancy is defined by median UICs of 150–249 µg/L (6).
The present literature review is a part of the NNR5 project with the aim of reviewing and updating the scientific basis of the 4th edition of the NNRs (4) issued in 2004 (Nord 2004:13). A number of systematic literature reviews will form the basis for establishment of dietary reference values in the 5th edition of NNR.
The overall aim was to review recent scientific data on health effects of iodine status (as an indicator of iodine intake). The specific objectives of the review were to assess the influence of different intakes of iodine at different life stages (infants, children, adolescents, adults, elderly, and during pregnancy and lactation), in order to estimate the requirement for adequate growth, development, and maintenance of health. In collaboration with the NNR5 horizontal group on pregnancy and lactation, we added one specific aim, that is, to assess the scientific evidence and special relevance for the Nordic setting by increasing the RDI of iodine during pregnancy and lactation from what was presented in the 4th edition of NNR.
Five research questions were developed:
The main functional or clinical outcomes of interest were pregnancy outcome, childhood development (including cognitive function and growth), thyroid function (thyroid hormones, thyroid gland size, hyper- and hypothyroidism), metabolism, health, and weight. See Appendix 1 for search terms. Out of the five research questions, only the studies related to the first three are presented in this review, the reason being lack of data related to research questions four and five.
Search terms were defined during spring 2010, in collaboration with Sveinn Olafsson, librarian at Landspitali The National University Hospital of Iceland, Reykjavik, Iceland. The search terms are presented in Appendix 1. The final search was run in September 2010, including all the relevant population groups and clinical outcomes, resulting in 1,516 abstracts. Studies published from January 2000 until September 2010 were included. Abstract screening was conducted in October and November 2010 according to the guide for conducting Systematic Literature Reviews for the 5th edition of the NNRs. Inclusion criteria in the abstract screening process were the following: relevant to iodine nutrition in the Nordic countries, Nordic or English language, ≥50 subjects, representative samples of the population or specific sub-samples of the population, preferably using UIC (spot samples or 24-h collections) as indicator of iodine status. Other potential indicators of iodine status and thyroid function, such as thyroid volume (TV), thyroid-stimulating hormone (TSH), T3 and T4, were also included. Most cross-sectional studies, only describing iodine status without clinical outcomes of interest for this review, were excluded at this point. Exceptions were studies conducted in one of the Nordic countries or studies with clinical outcomes of interest that might not be covered by data from cohort studies or intervention trials.
The overall aim of the present work was to review and update the scientific basis of the NNRs (NNR 4th edition), issued in 2004 (Nord 2004:13). As a systematic review was not used as basis for the NNR 2004, we decided to order some review papers along with original papers. The reason for this decision was also related to the special aim of the current review to assess the scientific basis for recently increased reference values from WHO/UNICEF/ICCIDD for pregnant women (6), and the relevance for the Nordic setting. All together 276 full papers were ordered, of which 108 papers were immediately excluded and not included in the full paper selection (86 overviews, 19 editorials, commentary, prize lectures, opinions or letters to the editors, and 3 publications that had been withdrawn), leaving 168 publications. Full paper screening was conducted in February 2011, where 128 papers were excluded, leaving 40 papers selected for quality assessment. Reasons for exclusion are provided in Appendix 2. The selected papers were grouped according to clinical outcomes and different age stages into the following categories: pregnancy and lactation, including endpoints such as birth outcome, development, and health of the offspring (n=16); children, including endpoints such as cognitive function and development (n=9); excessive iodine intake (n=4); and adults (n=2). Studies from the Nordic countries (n=13) were assessed separately in order to get an overview of iodine nutrition in the Nordic countries. Many of the Nordic studies only included descriptive information, while others were included in the relevant categories (according to clinical endpoints presented in each paper) at a later stage (n=4, all in the pregnancy and lactation category).
To evaluate the quality of the selected articles (n=40), we used the Quality Assessment Tool (QAT) received from the NNR5 secretary. The QAT included questions about study design, recruitment, compliance, dietary assessment, confounders, statistics, outcomes, and so on. The summary of findings from studies graded as A or B according to QAT are presented in summary Tables 1–6. Detailed information is provided in evidence tables (Appendix 3–7). Main results of the papers graded C are given in the text, but those studies are not used in the final grading of evidence. The grade of evidence was classified as convincing, probable, suggestive, and no conclusion, in line with criteria introduced in the Systematic literature review (SLR) guide for the 5th edition of NNR.
Author, year, (reference number.) | Population | No. of participants | Intervention/exposure | Outcome variable | Effect | Study quality | Comments |
Antonangeli et al. 2002 (7) | Pregnant women | n=67 | Supplementation of 200 µg/day vs. 50 µg iodine | UIC/TV | Six months after delivery UIC was 230 µg/g creatinine in group A and 128 µg/g creatinine in group B. NS difference in TV. | B | Observed difference in UIC after randomization, but no statistical test reported on if this difference is statistically significant. |
Nøhr & Laurberg, 2000 (9) | Pregnant women/Infants | n=144 | 150 µg iodine supplement (+I) or no iodine (no I). | TSH | Mothers in the +I group had lower TSH (mU/L), than the no I group. The +I group of neonates had higher TSH than the no I group. | B | The study suggests that iodine supplementation of the mother will, in general, not improve fetal thyroid function in areas such as Denmark with mild iodine deficiency. A slightly inhibitory effect may be expected, which is probably not of clinical significance. |
Nøhr et al., 2000 (8) | Pregnant women with thyroid peroxidase antibodies (TPO-Ab) | n=66 | 150 µg iodine supplement or no iodine supplementation. | Postpartum thyroid dysfunction (PPTD) | TPO-AB level at screening was a good predictor of the PPTD risk. No statistical significant difference in the frequency of PPTD in the three groups, with no significant increase in the prevalence, severity, or duration of PPTD when 150 mg iodine was given to TPO. | A | Unlikely that supplementation of 150 µg/day will have adverse effects in TPO-Ab women living in an area with mild to moderate ID. |
Author, year, (reference number) | Population | No. of participants | Intervention/Exposure | Outcome variable | Effect | Study quality | Comments |
Choudhury & Gorman, 2003 (15) | Children, 7 months and 13 months | n=135 | Prenatal iodine deficiency (cord blood TSH concentration); control group <5 mU/L, group 2 10.0–19.9 mU/L, group 3 20.0–29.9 mU/L and group 4 ≥30 mU/L. | Mental development index (MDI) | Infants in groups 3 and 4 had lower novelty preference (suggesting less efficient information processing) than infants in the non-elevated and the mildly elevated groups at 7 months. The three elevated TSH groups (2, 3, and 4) had significantly lower MDI scores than the non-elevated control group at 13 months. | B | No information on iodine nutrition (neither UIC nor iodine intake). |
Oken et al., 2009 (16) | Children, 6 months and 3 year | n=500 | Newborn T4 (thyroxine) levels and maternal thyroid function (plasma TSH, total T4 and TPO antibody levels) | Visual recognition memory (VRM) paradigm at 6 months. Cognition assessed at 3 year. | Higher newborn T4 was associated with slightly lower scores on the VRM test at 6 months. Newborn T4 levels were not associated with cognitive tests at 3 year. No evidence that impaired maternal thyroid function was associated with lower child cognitive test scores. | A | No information on iodine nutrition (neither UIC nor iodine intake). |
Author, year, (reference number) | Population | No. of participants | Intervention/exposure | Outcome variable | Effect | Study quality | Comments |
Gordon et al., 2009 (23) | Children, 10–13 years | I group n=84 and placebo n = 82. | 150 µg I tablet vs. placebo | Cognitive performance | Cognitive performance improved in the I group (2 out of 4 subtests) | B | Relevant in a Nordic perspective since the study is among children in mildly iodine-deficient area. |
Zimmermann et al., 2006 (24) | Children 10–12 years | I group n=159 and placebo n=151. | 400 mg iodine as oral iodized oil vs. placebo. | Cognitive and motor performance | Cognitive and motor performance improved in the I group (4 out of 7 subtests) | B | Study from an iodine-deficient area in Albania. Might not be relevant for the Nordic countries. |
Van den Briel et al., 2000 (25) | Children 6–12 years | Improved group (n=128), unchanged group (n=68). | Iodine status changed from severe iodine deficiency to moderate, from severe to normal-mild, or from moderate to normal-mild. | Mental and psychomotor performance | Greater increase in performance on the combination associated with improved iodine status | B | Study includes schoolchildren in Benin and reflects not Nordic countries |
Author, year, (reference number) | Population | No. of participants | Intervention/Exposure | Outcome variable | Effect | Study quality | Comments |
Ayturk et al., 2009 (32) | Newly diagnosed patients with metabolic syndrome (18–74 years) and controls living in a mild-to moderate iodine deficiency area | n=539; n=278 in the metabolic syndrome group (33.1% male) and n=261 in the control group (30.7% male) | Thyroid volume | TSH was significantly correlated with the presence of metabolic syndrome. Insulin resistance, waist circumference and triglycerides independent predictors of thyroid volume. | B | No information on iodine nutrition (neither urine iodine nor iodine intake). | |
Hoption Cann et al., 2007 (33) | Males 25–74 years | n=4,234 (n=197 cases) | Tertiles of iodine/creatinine categories (<201 µg/g n=1,452, 201–345 µg/g n=1,554, >345 µg/g n=1,228, referred to as low, moderate and high levels | Prostate cancer incidence | Risks of prostate cancer between tertiles of Iodine/creatinine categories NS after adjustments for potential confounding factors. History of thyroid disease was associated with greater than twofold increased risk. | B | The role of iodine remains speculative. A role of thyroid disease and/or factors contributing to thyroid disease as a risk factor for prostate carcinogenesis warrants additional investigation. |
Author, year, (reference number) | Population | No. of participants | Intervention/exposure | Outcome variable | Effect | Study quality | Comments |
Zimmermann et al., 2005 (34) | Children 6–12 years | n=3,319 | UIC <300 µg/L, UIC 300–500 µg/L, UIC >500 µg/L | Thyroid volume (TV) | UIC of 300–500 µg/L not associated with increased TV. TV started to increase at a UIC ≈ 500 µg/L. | B | The authors don‘t rule out adverse effects of UIC in the range of 300–500 µg/day not detected in this study |
Author, year, (reference number) | Population | No. of participants | Intervention/exposure | Outcome variable | Effect | Study quality | Comments |
Pedersen et al., 2002 (38) | Adults 18–65 years | n=310,124 in the Aalborg area and n=225,707 in the Copenhagen area | Mandatory salt iodization (13 µg/g) | Incidence rates of hyper- and hypothyroidism | Iodine supplementation may increase the incidence of overt hypothyroidism even if the population is moderately iodine deficient. | B | The optimal level of iodine intake to prevent thyroid disease may be a relatively narrow range around 150 µg/day. |
Rasmussen et al., 2009 (39) | Adults 18–65 years | n=4,649 and n=3,570 | Mandatory salt iodization (13 µg/g) | UIC and FFQ | Iodine excretion (µg/L and µg/24 h) increased significantly in all age and sex groups. | B | Iodine intake is at recommended level, however in the youngest age groups in both cities and in women aged 40–45 year living in Aalborg, the iodine intake is below the recommendation. No groups with excessive iodine intake were identified. |
Vejbjerg et al., 2007 (40) | Adults 18–65 years | n=4,649 and n=3,570 | Mandatory salt iodization (13 µg/g) | Thyroid volume | Lower thyroid volume in all age groups | B | The decline in thyroid volume was largest in the regions with former moderate iodine deficiency. |
Vejbjerg et al., 2008 (45) | Adults 18–65 years | n=4,649 and n=3,570 | Mandatory salt iodization (13 µg/g) | Thyroid volume and TSH in relation to smoking. | Smokers have lager thyroid volume than non-smokers; however, the difference in thyroid volume was reduced after iodization. The effect of smoking on TSH and free T4 was unchanged after iodization. | B | The effect of smoking on thyroid volume seems to be dependent on iodine intake. |
Vejbjerg et al., 2009 (41) | Adults 18–65 year | n=4,649 and n=3,570 | Mandatory salt iodization (13 µg/g) | TSH and prevalence of thyroid dysfunction | Higher TSH level after iodization in both regions and across age groups. Lower prevalence of mild hyperthyroidism and increased prevalence of hypothyroidism related to a higher iodine intake. | B | Increased iodine intake after mandatory iodization change the pattern of thyroid dysfunction in the population. |
Studies relating iodine status during pregnancy to maternal and/or neonatal thyroid function are presented in Table 1 (details are provided in Appendix 3). An Italian trial (7) assessed iodine status and thyroid function in women after supplementation of 200 µg iodine or 50 µg iodine per day during pregnancy and up to 6 months after delivery. Improved iodine status was observed in both groups, but no difference in thyroid function was found between groups. The most relevant studies in the Nordic perspective are those from Denmark (8, 9). The study by Nøhr and Laurberg (9) included healthy pregnant women with no previous history of thyroid disease, comparing maternal and neonatal thyroid function between mothers receiving 150 µg iodine as a supplement during pregnancy to those not receiving any supplements. Although small difference in thyroid function was seen between groups, the study suggests that iodine supplementation of the mother will, in general, not improve fetal thyroid function in areas such as Denmark with mild iodine deficiency. A randomized controlled trial was conducted by the same research group among women with thyroid peroxidase antibodies (TPO-Ab), showing that it is unlikely that supplementation of 150 µg/day will have adverse effects in TPO-Ab women living in an area with mild-to-moderate ID (8).
Iodine nutrition of pregnant women from Norway (n=119) was studied by Brantsæter (C-study) and colleagues (10). Women using dietary supplements had median iodine intake of 215 µg/day (range 106–526) compared with 122 µg/day (range 25–340) among non-supplement users. The median UIC was also significantly higher in iodine supplement users (190 µg/24 h for FFQ and 220 for FD) than in non-supplement users (110 µg/24 h) (10).
All studies in this category were evaluated as low-quality studies (C) due to high drop-out rate, or other methodological issues (data not shown). Higher birth weight of infants whose mothers had UIC 50–99 µg/L compared with those with UIC < 50 µg/L was reported in a cohort study from Spain (11). Three more studies assessed the association between iodine status and reproductive failure (12) or pregnancy complications (13–14).
Table 2 (details are provided in Appendix 4) describes studies relating prenatal indicators of iodine status to cognitive function in the offspring. In the study by Choudhury and Gorman (15), Chinese infants were stratified into iodine deficiency groups (ID) by cord blood TSH concentration. Lower mental developmental index (MDI) was observed in the group with highest cord blood TSH. The third study in Table 2 describes results from Project Viva (16) where associations between maternal as well as newborn thyroid function and cognitive function were assessed. Higher level of T4 in newborns was associated with slightly lower scores on the visual recognition memory test at 6 months. However, no association was observed between maternal or newborn thyroid function and cognitive function at 3 years. It should be noted that low number of women had abnormal thyroid function in the study. Other studies in this category were quality graded as C-studies, as the statistical analysis was questioned or potential confounding factors not adjusted for (data not shown). The Berbel study (17) was a non-randomized intervention study where iodine supplementation (200 µg KI/day) was initiated at 4–6 weeks or 12–14 weeks of pregnancy or after delivery. The study suggests that delay in maternal iodine supplementation increases the risk of neurocognitive developmental delay of their offspring. Only 11–12% of the total study population was included in the analysis as the authors established extensive exclusion criteria in order to obtain comparably homogenous groups of children. In a non-randomized intervention study by Velasco and colleagues from 2009, pregnant women were provided with 300 µg iodine in the intervention group, while a control group received no supplementation. Psychomotor development index (PDI, which is one of three scales of the Bayley Scales of Infant Development used in the study) was significantly higher in children of mothers in the intervention group than the control group (18). However, lactation was found to be a confounding factor explaining the variance in the PDI. Other possible confounding variables were not controlled for and the results should therefore be considered as preliminary. In a study from China, cognitive function was assessed in children (5- go 7-year-old follow up) whose mothers initiated iodine supplementation during different stages of pregnancy (early: 1st, 2nd or late: 3rd trimester) and in a control group of children receiving iodine supplementation from 2 years of age (19). The main results point towards the suggestion that children would benefit from their mothers iodine supplementation during pregnancy in the particular population studied.
The literature search did not result in many papers related to lactation, and only three papers in this area were selected for quality assessment. A Danish study from 2004 (B study according to quality assessment), that was already included in the NNR 4th edition (4, 20), showed that the level of iodine in the breast milk of smokers was 26.0 µg/L (23.2–29.1 µg/L) and in non-smokers 53.8 µg/L (49.4–58.5 µg/L), p < 0.001. Significant differences were also found in the infants, as the urinary iodine in infants with smoking mothers was 33.3 µg/L (29.9–37.2) versus 50.4 µg/L (46.0–55.1 µg/L) in non-smokers. Although the main message to breastfeeding mothers would be not to smoke, this study highlights the importance of obtaining enough iodine from the diet or through supplementation.
Several methodological issues (such as low participation rate and lack of adjustments for potential confounders) where observed during quality assessment of the other two studies in this category (21–22). UIC was higher in formula-fed infants than breastfed in a study from New Zealand, although no information was provided on the iodine status of the lactating mothers (21). In an Australian study, a correlation between iodine status of the mothers and iodine content of breast milk was found (22).
Results of three studies are presented in Table 3 (details are provided in Appendix 5) (23–25), all suggesting improved cognitive function in 6- to 13-year-old children related to iodine supplementation or improved iodine status. The results from the Gordon study, performed in New Zealand, might be relevant in the Nordic setting since the study includes children from a mildly iodine-deficient area (UIC 63 µg/L at baseline). The study suggests that mildly iodine-deficient children might benefit from iodine supplementation of 150 µg/day, in order to attain their full intellectual potential. However, the two other studies might not be relevant in the Nordic perspective, including children from iodine-deficient area of Albania and North Benin. A cross-sectional study from Spain points in the same direction (26), where an intelligence quotient below the 25th percentile was significantly related to UI below 100 µg/L (OR 1.4, p=0.02), adjusted for potential confounding factors (data neither shown in Table 3 nor included in grading of evidence).
Only cross-sectional studies were retrieved studying the relationship between iodine status or iodine supplementation and outcomes such as hearing (27), body composition (28, 29), growth, and insulin-like-growth factor-I (30). References to these studies are only included in this review for informational purpose as cohort studies or intervention studies were lacking (data not shown). In an intervention study by Zimmerman (graded as B study) iodine-deficient children (UI at baseline 46 µg/L) were supplemented with iodized oil or iodized salt for 5–6 months. A significant increase was observed in UI in the iodine group (UI 158 µg/L at endpoint), while total and LDL-cholesterol concentration as well as C-peptide decreased (data not shown) (31).
The literature search did not result in many studies, including adults and elderly in relation to iodine. Only two publications were selected for quality assessment in this category, both graded as B studies (Table 4, details are provided in Appendix 6). Subjects with the metabolic syndrome were found to have increased TV and nodule prevalence, and insulin resistance was suggested as an independent risk factor for nodule formation in an iodine-deficient environment (32). However, no information was provided on iodine nutrition (neither urine iodine nor iodine intake), making the study less relevant for the purpose of NNR. Prostate cancer incidence according to UIC concentration (7- to 21-year follow-up) was assessed in the First National Health and Nutrition Examination Survey Epidemiological Follow-up Study (NHEFS) (33). After adjustments for potential confounding factors, the association found turned out to be non-significant. However, reported history of thyroid disease was associated with greater than two-fold increased risk of prostate cancer.
Four studies related to excessive iodine intake were a subject to quality assessment by the group. In children, UIC ≥ 500 µg/L was found to be associated with increasing Tvol in 6- to 12-year-old children, while UIC 300–500 µg/L was not (34) (Table 5, details are provided in Appendix 7). Results of other selected papers in this category should be interpreted with caution due to lack of information, especially related to adjustments for potential confounding factors (35–37) (data not shown). A prospective community-based survey among 13-year-old Chinese children, examined again 5 years later, found no difference in occurrence of autoimmune hyperthyroidism between communities with median UIC of 88, 214, and 634 µg/L (35). A case–control study (36) showing small but significant difference in UIC between women with autoimmune subclinical hypothyroidism and the matched controls (327±113 vs. 274±99 µg/L, p < 0.01), and a Chinese cohort study by Guan et al. (37) suggested that post-partum thyroiditis (PPT) in pregnant women is triggered by high (defined as UIC > 300 µg/L) iodine intake.
The majority of the studies in the area of iodine nutrition from the Nordic countries are from Denmark. In total, 13 studies from Nordic countries were selected for quality assessment. Results of four of them have already been presented in the section on pregnancy and lactation (8–10, 20). Main results of the studies from the Nordic countries are presented in Tables 6 and 7.
Country, author, year (reference number) | Location, year of study | Method | Number of subjects and gender | Age (years) | Iodine excretion and thyroid function | Iodine intake |
Denmark, Rasmussen et al. 2008 (39) | Aalborg and Copenhagen 1997–1998 and 2004–2005. | FFQ, spot urine and estimated 24 h I excretion | 4,649 subjects in 1997–1998 (before fortification) and 3,570 comparable subjects in 2004–2005 (after fortification). | 18–65 | Median I excretion (25th, 75th): From non-fortified food intake: 1997–8: 61 µg/L (34, 101) or 94 µg I/24 h (60, 159). 2004–5: 101 (57, 151) or 145 µg I/24 h (100, 146). From non-supplement users: 1997–8: 78 µg I/24 h (52, 116). 2004–5: 128 µg/L (92, 183). From supplement users: 1997–8: 157 µg I/24 h (92, 267). 2004–5: 222 µg I/24 h (145–346). | Median I intake (25th, 75th) from non-fortified food: 1997–8: 109 µg/day (79, 149). 2004–5: 110 µg/day (82, 146). Milk was the strongest determinant of I intake. |
Iceland, Gunnarsdottir et al. 2010 (48) | Reykjavik, June 2007–2008 | FFQ as personal interview, spot urine and blood. | 112 adolescent girls | Born 1987–1992 | Median 200 µg/L (20th was 90 and 80th was 320). Average TSH of 2.0±1.2 mU/L. | Average dietary I intake was 170 µg/day. 10% had I intake below 70 µg and none was above 600 µg. (Milk and dairy products provided 43%, fish 24% and supplements 9% of the total dietary I). |
Norway, Brantsæter et al. 2007 (10) | Pregnant women in MoBa study at Bærum Hospital. | FFQ, 4-day weighed food record and 24-h urine sample. | 119 women | 23–44, mean age of 31. | Supplement users FFQ: UI of 180±75 and median 190 µg/24 h. Supplement users food diary: UI 220±110 and median 220 µg/24 h. Non-supplement users: UI 140±90, median 110 µg/24 h. | Supplement users: FFQ I intake of 211±86, range 106–526 µg/day. Food diary I intake of 214±64, range 103–355 µg/day, Non-supplement users: FFQ I intake of 138±38, range 25–340 µg/day. Food diary I intake of 117±42 and range 42–222 µg/day. |
Norway, Dahl et al. 2003 (50) | Tromsø, 1999 and Bergen, 2001 | Casual urine TSH and free T4 | 32 men and 28 women in Tromsø. 9 men and 35 women in Bergen. | 23–64 in Tromsø and 21–49 in Bergen. | Tromsø: 132 (38–572) µg I/L in men, 112 (57–314) µg I/L in women TSH 1.4 mIU/L in men, 1.8 mIU/L in women Free T4 15 pmol/L in men and women. Bergen: 106 (25–182) µg I/L or 140 (33–235) µg I/24 h in men, 82 (8–348) µg I/L or 79 (16–316) µg I/24 h in women, TSH 1.3 (0.5–4.2) mIU/l in men and women, free T4 12 (10–16) pmol/l in male and women | Tromsø: Men 187 and women 114 µg I/day. Bergen: Men 147 and women 75 µg I/day. |
Sweden, Anderson et al. 2009 (46) | Representative national samples collected between Oct 2006 and May 2007. | Spot urine | 857 school aged children. 445 boys and 412 girls. | 6–12 | Median UIC was 125 µg/L, range 11–757. 36% had <100 µg/L, 3% had >300 µg/L. | NA |
Sweden, Milakovic et al. 2004 (47) | Semi-rural community (Mölnlycke) | Spot urine Thyroid volume | Group 1: 38 boys and 23 girls. Group 2: 12 boys and 38 girls. Group 3: 57 adults | Group 1: 7–9. Group 2: 15–17. Group 3: 60–65. | Median urinary iodine concentration was in group 1: 194 µg/L, group 2: 246 µg/L and group 3: 190 µg/L. Median (range) of thyroid volume was in group 1: 4.7 mL (2.9–17), in group 2: 11.5 mL (5.6–32) and in group 3: 14.3 mL (3.1–33). | NA |
The Danish Investigation of Iodine Intake and Thyroid Disease (DanThyr) is the official clinical monitoring of the Danish iodine supplementation program, which prospectively measure the incidence rates of hyper- and hypothyroidism in the cities of Aalborg and Copenhagen. In the first examination in 1997–98, the Aalborg area was found to be in the range of moderate iodine deficiency, whereas the area around Copenhagen had mild iodine deficiency (38). The difference in iodine intake in these two areas can mainly be explained by the difference in iodine content in drinking water (5 µg/L in Aalborg and 18 µg/L in Copenhagen) (39). In 2000, it became mandatory to fortify all salts used in bread and household with iodine at a level of 13 µg/g. In 2004–2005, the urinary iodine excretion had increased significantly in all age groups compared with before mandatory iodine fortification in both areas. For instance, the median-estimated 24-h urinary iodine excretion in both areas was 78 µg/day before iodization and 140 µg/day after iodization among non-supplement users. The corresponding median UIC in both areas increased from 61 µg/L in 1997–1999 to 101 µg/L in 2004–2005 (39). However, the iodine intake in the youngest age groups in both cities and in women aged 40–45 years in the Aalborg area was still below the recommendation after the mandatory iodization of salt (39). Milk, water, and salt intake were determinants of iodine intake in 2004–2005, whereas bread and fish intake were not related with iodine intake (39).
The studies from Denmark based on the DanThyr programme shows marked differences in pattern of thyroid dysfunction with different iodine intakes (40, 41) and the optimal level of iodine intake to prevent thyroid disease may be a relatively narrow range around the recommended daily iodine intake of 150 µg (42). In general, mild and moderate iodine deficiency is associated with more hyperthyroidism and less hypothyroidism than high iodine intake (42). In 1997–1998, the incidence rate of hyperthyroidism was higher in the Aalborg area with moderate iodine deficiency (with UI of 45 µg/L) compared with the Copenhagen area with higher iodine intake (mild iodine deficiency) (with UIC of 61 µg/L) (38). Further, hyper- and hypothyroidism were more common in females than in males in both areas, and the incidence rates of both hyper- and hypothyroidism increased with age. In the Copenhagen area, a higher incidence rate of hypothyroidism was found compared with the Aalborg area.
Even the small differences in UIC from mild (61 µg/L) and moderate (45 µg/L) iodine deficiency areas in Denmark showed marked differences in the prevalence of goiter with 9.8% goiter in the mild iodine deficiency area (Copenhagen) and 14.6% goiter in the moderate iodine deficiency area (Aalborg) (43, 44).
A lower TV was seen in all age groups independent of sex after iodization and the decline was largest in the Aalborg area with former moderate iodine deficiency (40). The level of TSH was also found to increase from 1.30 mUI/L to 1.51 mUI/L in both regions and across age groups after the introduction of iodization of salt (41). The increase was expected as populations with iodine sufficiency in general have a higher level of TSH than populations with iodine deficiency (41). The effect of smoking on hormonal levels of TSH and free T4 were unchanged after the iodization, however, increased iodine intake had an effect on the TV of smokers, as the difference in TV between heavy smokers and non-smokers was reduced after iodization of salt (45).
A cross-sectional study of Swedish national data on UIC of children aged 6–12 years indicated adequate iodine nutrition, and there were no gender or age differences in median UIC of the children (46). This study provides evidence that the voluntary addition of iodine to salt since 1,936 at a level of 40–70 mg/kg is sufficient to ensure adequate iodine nutrition in the Swedish population (46). Iodized table salt remains the main dietary source of iodine in the diet and among adults it is estimated to provide more than 50% of the iodine intake in Sweden (46). In another Swedish cross-sectional study among small groups of children, teenagers, and adults, the median UIC suggested adequate iodine nutrition (47).
A cross-sectional study including adolescent girls from Iceland found optimal iodine status; however, the result should be used with cation, as only 39% completed the study. Still the results are good estimates of the iodine nutrition of adolescent girls from Iceland (48).
Results from a representative study in Norway suggest that the dietary iodine intake is in the range considered to be sufficient among adults and children; however, it decreased among adolescents, especially among girls (49). Regular intake of milk, dairy products, and seafood are of importance to secure adequate iodine intake in Norway as the iodization of salt (only table salt) is very low (5 µg/g). This was clearly shown in the study including subjects with a variable intake of fish and dairy products, which indicated mild iodine deficiency among subjects having low intake of these two food groups (50).
Iodine deficiency remains a major threat to the health and development of populations around the world, and it is claimed that much of Europe is iodine deficient (51). The iodine status in all the Nordic countries is not well documented; however, based on UIC, the iodine nutrition status in Denmark, Iceland, Finland, and Sweden is sufficient and it is deficient in Norway according to WHO data (51).
The overall aim was to review recent scientific data on health effects of iodine status (as an indicator of iodine intake) in order to update current Nordic dietary reference values and to assess the scientific evidence and special relevance for the Nordic setting by increasing the RDI of iodine during pregnancy and lactation from what was presented in the 4th edition of NNR.
Grading of evidence is presented in Table 8. It should be emphasized that the grading of evidence is only based on studies from 2000–2010 and in some cases inclusion of earlier studies might have resulted in different grading. Evidence supporting that iodine supplementation during pregnancy is associated with maternal iodine status and thyroid function is suggestive (7, 9). One A study and one B study showed improved cognitive function of infants and children up to 18 months with potential indicators of improved iodine status of the mother (15, 16), while the evidence for improved cognitive function in older children is limited. It should be noted that no direct measurements of iodine intake where used in these studies (15, 16), and the conclusions are therefore based on the association between thyroid function (as an indicator of iodine status) and cognitive function of the offspring. The relevance of these studies to be used to set recommendations on iodine intake might therefore be questioned. Moderately to severely iodine-deficient children (6–13 years) will probably benefit from iodine supplementation or improved iodine status in order to improve cognitive function (23–25, 31), while only one study showed improved cognitive function with iodine supplementation in children from a mildly iodine-deficient area (23). No conclusions can be drawn related to other outcomes included in our search. A second literature search (using the same search string as previously) was conducted in March 2012, including studies published in the period October 2010 to February 2012. No additional studies were included in this review, as it would not modify the conclusions drawn from the studies included.
Grading of evidence* | Number of studies | References | |
Iodine supplementation during pregnancy is related to improved maternal iodine status and/or thyroid function. | Suggestive | Two B studies | Antonangeli et al. 2002 (7); Nøhr & Laurberg, 2000 (9) |
Iodine supplementation during pregnancy is related to infant thyroid function. | No conclusion | One B study | Nøhr & Laurberg, 2000 (9) |
Iodine supplementation of pregnant women with thyroid peroxidase antibodies (TPO-Ab) is not associated with adverse effects. | |||
No conclusion | One A study | Nøhr et al., 2000 (8) | |
Improved prenatal iodine status is associated with improved cognitive function of infants and children up to 18 months. | Suggestive | One A study and two B studies | Oken et al. 2009 (16); Choudhury & Gorman 2003 (15) |
Improved prenatal iodine status is associated with improved cognitive function in children above 2 years. | No conclusion | One A study | Oken et al. 2009 (16) |
Iodine supplementation improves iodine status in mildly, moderately and severe iodine-deficient children (7–13 years). | Probable | Four B studies | Gordon et al., 2009 (23); Zimmermann et al., 2006 (24); van den Briel et al., 2000 (25); Zimmerman et al., 2009 (31). |
Iodine supplementation or improved iodine status improves cognitive function in moderately to severe iodine-deficient children aged 6–13 years. | Probable | Three B studies | Gordon et al., 2009 (23); Zimmermann et al., 2006 (24); van den Briel et al., 2000 (25) |
Iodine supplementation improves cognitive function in mildly iodine-deficient children aged 10–13 years | No conclusion | One B study | Gordon et al., 2009 (23) |
Iodine supplementation is related to improved lipid profile in children | No conclusion | One B study | Zimmerman et al., 2009 (31) |
Iodine status of adults is associated with features of the metabolic syndrome. | No conclusion | One B study | Ayturk et al., 2009 (32) |
Iodine status is related to risk of prostate cancer. | No conclusion | One B study | Hoption Cann et al., 2007 (33) |
Excessive intake of iodine (UIC 300–500 or >500 mcg/L) is associated with adverse effects in children. | No conclusion | One B study | Zimmermann et al., 2005 (34) |
Surprisingly, dietary data was only included in a very low number of studies. Furthermore, in many cases the exposure was thyroid function rather than estimate of iodine intake (i.e. UIC). Definitions of severe, moderate, and mild iodine deficiency also vary between studies. It is therefore challenging to use information from the studies included in this review in order to set dietary reference values.
There are no new data supporting changes in dietary reference values for children or adults. Although the WHO/UNICEF/ICCIDD has increased the RDI for iodine from 200 to 250 µg/day in pregnancy and in lactating women (6), they emphasized the need for more data on the level of iodine intake that ensures maternal and newborn euthyroidism. The iodine requirement during pregnancy is increased because the mother synthesizes ∼50% more iodine-containing thyroid hormones to maintain maternal euthyroidism and to transfer thyroid hormones to the fetus and because the mother has increased renal losses of iodine (3). The rationale for increasing the dietary reference values for pregnant and lactating women in the 5th edition of NNR needs to be discussed in a broad perspective taking into account iodine status of pregnant women in the Nordic countries. Nordic studies retrieved have mainly described the thyroid function rather than the intake and sources of iodine in the diet. Further studies are required, especially among the most vulnerable groups, but also studies which assess possible adverse effects of high intake of iodine.
Special thanks to Sveinn Olafsson, Jannes Engquist, Ulla-Kaisa Koivisto Hursti, and Wulf Becker for their help and guidance throughout the whole process.
The authors have not received any funding or benefits from industry or elsewhere to conduct this study.
*Ingibjörg Gunnarsdottir
Unit for Nutrition Research
University of Iceland and Landspitali The National University Hospital of Iceland
Eiriksgata 29, IS-101 Reykjavik, Iceland
Email: ingigun@hi.is
Search terms
Date: September 2010
Database: PubMed/Medline
(Humans[MeSH Terms]) OR human*[Title/Abstract]
Iodine[MeSH Terms]
Growth and development[Title/Abstract]) OR Thyroid gland[MeSH Terms]) OR Thyroid gland size[Title/Abstract]) OR Thyroid hormones[MeSH Terms]) OR Metabolism[Title/Abstract]) OR Hyperthyroidism[MeSH Terms]) OR Hypothyroidism[MeSH Terms]) OR Overweight[Title/Abstract]) OR Obesity[MeSH Terms]) OR Pregnancy[MeSH Terms]) OR pregnancy*[Title/Abstract]) OR Life style[Title/Abstract]) OR excessive[Title/Abstract]) OR insufficient[Title/Abstract]) OR iron[MeSH Terms]) OR selenium[MeSH Terms]) OR Urinary iodine concentration[Title/Abstract]) OR Iodine status[Title/Abstract]) OR Maternal Iodine intake[Title/Abstract]) OR Neonatal TSH[Title/Abstract]) OR cognition[Title/Abstract]) OR child development[MeSH Terms]) OR Child development[Title/Abstract]) OR infant development[Title/Abstract]) OR maternal iodine status[Title/Abstract]]
(1504 hits)
Search terms
Date: September 2010
Database: SveMed +
Iodine[MeSH Terms]
(12 hits)
Reference, details, first author year, country | Study design | Population, subject | Outcome measures | Intervention/exposure | Time between baseline exposure and outcome assessment | Dietary assessment method | No. of subjects analyzed | Intervention | Follow-up period, drop-out rate | Results | Confounders adjusted for | Study quality and relevance, Comments A-C |
Antonangeli et al., 2002, Italy (7) | Clinical trial | pregnant women (n=86), 20–38 years, enrolled from 10th to the 16th week of gestation. Women with clinical and laboratory evidence of hyperthyroidism, hypothyroidism, thyroid autoimmunity (thyroid autoantibodies >1:400) or thyroid volume greater than 20 mL were excluded. After recruitment 7 women withdrew their consent and 12 dropped out of the study (eight because of serious gestational events). After randomization the UIE was 91 mcg/g creatinine in group A and 65.5 mcg/g creatinine in group B. | UIE (casual urinary samples), TV, FT4, FT3, TSH, Tg. | Group A received on table iodide 200 per day (200mcg/d) and group B received 1/2 tablet iodide 100 (50 mcg/day). | Subjects assessed at 18th-26th week, 29th-33rd week, 3rd and 6th month after delivery. | No assessment of dietary intake. | n=67 (A n=32 and B n=35). | 200 mcg iodine vs. 50mcg iodine. | Follow-up period from the first trimester throughout pregnancy to 6 months after delivery (approx. 12–14 months). Drop-out 22.1%. | Six months after delivery UIC was 230 mg/g creatinine in group A and 128 mg/g creatinine in group B. No difference in TV, Thyroid function or clinical events found between groups. | None reported. | B No information how women were randomized into groups. Observed difference in UIE after randomization, but no statistical test presented if this difference is statistically significant. Neither information on lactation nor iodine intake from other sources reported. |
Nøhr & Laurberg, 2000, Denmark (9) | Cohort study | Healthy pregnant women with no previous history of thyroid disease, from 5 different regions of Denmark (n=152). Women with regular daily intake of multivitamin and mineral tablet containing iodine (150 mcg) during pregnancy (+I group, n=50) and women with no artificial iodine supplementation (no I group, n=96) continued this study, whereas women who had a history of intermittent iodine supplementation (n=6) where excluded. Median UI in the +I group was 60 mcg/L and 34.5 mcg/L in the no I group. | Maternal and neonatal thyroid function. UI measured in a spot sample on day 5 after delivery. | The participants were instructed to continue their previous vitamin and mineral supplementation during the puerperal period. 150mcg/day or no artificial iodine. The women had been recommended to take vitamin and mineral supplementation as part of normal pregnancy care. | Mother and infant at term and infant on day 5. | Not reported. | n=146. Blood samples from mothers shortly after admission for labor n=144, mixed cord blood samples n=139. | Mothers in the +I group had lower TSH (mU/L), higher free T4 (nmol/L) and lower Tg (mg/L) than the no I group (median (25–75%); 2.06 (1.49–2.47) vs. 2.23 (1.65–3.08), 8.4 (7.5–9.7) vs. 7.9 (7.0–8.8) and 14.7 (7.1–25.2) vs. 25.8 (16.4–53.4), respectively, p<0.05. The neonates showed a pattern different from the mothers. The +I group of neonates had higher TSH than the no I group; 9.00 (6.18–14.81) vs. 7.07 (4.72–11.58), while T4 was higher and Tg was lower in the neonatal +I group than in the no I group, similar to that in the mothers. | Age, parity, gestational length or birth weight of the neonates were not different between groups. | B The study suggest that iodine supplementation of the mother will, in general, not improve fetal thyroid function in areas such as Denmark with mild iodine deficiency. A slightly inhibitory effect may be expected, which is probably not of clinical significance. | ||
Nøhr et al., 2000, Denmark (8) | RCT, double blind trial | Women with thyroid peroxidase antibodies (TPO-Ab) n=117 (prevalence 9.1%) from the healthy pregnant Danish women cohort (age 18–35 years, n=1284), screened at week 11 (median). 72 TPO-Ab women agreed to participate (61.5% of the eligible population). Randomised and stratified according to TPO-Ab level to three groups. | Postpartum thyroid dysfunction (PPTD) defined as abnormal TSH in the postpartum period (subclinical hypothyroidism if only TSH was abnormal and clinical hypothyroidism if TSH and thyroid hormones were abnormal). | 150 mcg iodine supplement or no iodine. Group +/+ (n=22/22) pregnancy and postpartum, Group +/−(24/20 in pregnancy only and Group -/- (26/24) received no supplements. | Thyroid function evaluated at 11 w, 35 w, gestation and 3, 5, 7, and 9 months postpartum. | Compliance was evaluated by 24-h urinary iodine measurements at time of inclusion, 35 w of pregnancy and 7 months postpartum. | n=66 | Follow-up from gestational week 11 throughout pregnancy and to 9 months postpartum. Drop-out 8%. | No statistical significant difference in the frequency of PPTD in the three groups, with no significant increase in the prevalence, severity, or duration of PPTD when 150 mcg iodine were given to TPO-Ab positive women during pregnancy only or during pregnancy and the post-partum period. | Smoking, group, age and parity. | A Unlikely that supplementation of 150mcg/day will have adverse effects in TPO-Ab women living in an area with mild to moderate ID. |
Reference, details, first author year, country | Study design | Population, subject | Outcome measures | Intervention/exposure | Time between baseline exposure and outcome assessment | No. of subjects analyzed | Follow-up period, drop-out rate | Results | Confounders adjusted for | Study quality and relevance, Comments A-C |
Choudhury & Gorman 2003. China (15) | Cohort study | Infants (n=284) from a non-endemic region of Northern China. No information on how they were selected to the study. Stratification of infants into iodine deficiency groups (ID) by cord blood TSH concentration (group 1 (control) <5 mU/L, group 2: 10.0–19.9 mU/L, group 3: 20.0–29.9 mU/L, group 4 ≥30 mU/L). Gender distribution in groups approximately equal. | Infant information processing (FTII) at 7 months (n=275). Infant cognitive and motor development (BSID-II) at 13 months (n=135). The BSID-II was subdivided into mental development index (MDI) and psychomotor development index (PDI) | Prenatal iodine deficiency (cord blood TSH concentration); control group <5 mU/L, group 2: 10.0–19.9 mU/L, group 3: 20.0–29.9 mU/L and group 4 ≥30 mU/L. | 7 and 13 months | n=275 at 7 months and n=135 at 13 months | FTII at 7 months available for 96% of the original group. BSID-II at 13 months available for 49% of the original group. | Infants in the highest TSH cord blood concentration groups (3 and 4), had lower novelty preference (57.7±5.6 and 57.5±3.1, respectively) (suggesting less efficient information processing) than infants in the non-elevated and the mildly elevated groups (1 and 2, 59.6±3.0 and 58.9±4.3, respectively, p<0.05). The three elevated TSH groups (2,3 and 4) had significantly lower MDI scores than the non-elevated control group (98.2±8.3, 98.7±9.3 and 93.5±11.1 vs. 102.5±8.2 respectively, p<0.05). No difference in PDI between groups. | Maternal education, place of residence (rural vs. urban) and maternal occupation. | B No information on iodine nutrition (neither urine iodine nor iodine intake). The overall novelty preference score and MDI score was well within the expected range in all groups. |
Oken et al. 2009. USA (16) | Cohort study | Children, 6 months and 3 years (50.4% male) of mothers who enrolled in the Project Viva cohort between 1999 and 2002. Women attending their initial prenatal visit (n=2128) at one of eight urban and suburban obstetrical offices in a multi-specialty group practice in Massachusetts. Eligibility criteria included fluency in English, gestational age less than 22 wks, singleton pregnancy, and plans to remain in the study area. Of 2128 women in the Project Viva who delivered a live infant, 988 had info on first trimester diet and infant cognitive testing at 6 months, and were thus eligible for inclusion in the present study. Maternal T4 (mcg/dL) 9.98 ±1.95 (n=496). | Cognitive testing using the visual recognition memory (VRM) paradigm at 6 months. Cognition assessed using two tests at 3 years: the Peabody Picture Vocabulary Test (PPVT) and Wide Range Assessment of Visual Motor Ability WRAVMA) | New born T4 (thyroxine) levels and maternal thyroid function (plasma TSH, total T4 and TPO antibody levels) | 6 months and 3 years | n=500 (missing data for some measurements). | 6mo and 3 years. Out of 988 eligible, 500 gave consent. | Higher newborn T4 was associated with slightly lower scores on the VRM test at 6 months (-0.5;95%CI -0.9, -0.2). Newborn T4 levels were not associated with scores on either the PPVT or WRAVMA at age 3 years. No evidence that impaired maternal thyroid function was associated with lower child cognitive test scores. | Maternal age, race/ethnicity, education, post-partum depression, mode of delivery, smoking, first trimester thyroid function, fish intake, intake of iodine-containing vitamins, thyroid medication use during pregnancy, diagnosed thyroid disease did not change the effect estimates. | A No information on iodine nutrition (neither urine iodine nor iodine intake). Low number of women with abnormal thyroid function. |
Reference, details, first author year, country | Study design | Population, subject | Outcome measures | Intervention/exposure | Time between baseline exposure and outcome assessment | Dietary assessment method | No. of subjects analyzed | Intervention | Follow-up period, drop-out rate | Results | Confounders adjusted for | Study quality and relevance, Comments A-C |
Gordon et al., 2009. New Zeeland (Dunedin) (23) | RCT, double-blind. | Children, 10–13 years, no known history of thyroid conditions, not taking I supplement. 162 children recruited from schools, 22 from advertisement, all together 184. 55% boys. Baseline UIC 63 mcg/L, Thyroglobulin 16.4 mcg/L, Total Thyroxine 104±28.1 nmol/L. | Cognitive performance. Wechsler Intelligence Scale for Children. Subtests: Picture concepts, matrix reasoning, symbol search, letter-number sequencing. | 150 mcg I tablet vs. Placebo. | 28 wk | FFQ, foods considered as main sources of I. Caregiver completed a FFQ about intake of dairy products, milk, red meat, poultry, fish, shellfish, pulses and legumes, fruit, eggs, and iodized salt. | n=166. I group n=84 and placebo n= 82. | Children were provided with 4-wk supplements in 28-day compliance packaging blister packs and an information sheet how to take their supplements. Every 4 wks a new pack of supplements was posted. Return envelope included to collect previous months supplements. If a pack was not returned, the compliance was assumed to be zero for that month. Movie vouchers, small stationary items, or shopping vouchers were sent out during the study to aid with compliance. | 11 drop-out in I group, 7 in placebo. Total drop-out 11%. | After 28 wk: I group UIC 145 mcg/L, Thyroglobulin 8.5 mcg/L. Placebo group UIC 81 mcg/L, Thyroglobulin 11.6 mcg/L. 2 of 4 cognitive subtest significantly improved in the I group. Perceptual reasoning in mildly ID children were improved in I group. Picture concept associated with 0.81 age-standardized point improvement in iodine relative to placebo (p=0.023), and 0.63 points in matrix reasoning (p=0.040). | Sex, method of recruitment, cohort, ethnicity and household income. | B Results are important and relevant in a Nordic perspective since the study is among children in mildly iodine-deficient area. Suggest that mild ID could prevent children from attaining their full intellectual potential. |
Zimmermann et al., 2006. Albania (24) | RCT, double-blind | All children - 10–12 years at 7 primary schools in villages in the Korce/Pogradec district of southeastern Albania were invited, n=310 (166 boys and 144 girls). | Morning spot urine, TSH, total thyroxine (TT4) and thyroid gland volume. 7 cognitive and motor skills tests (measures of information processing, working memory, visual problem solving, visual search and fine motor skills). | 400 mg iodine as oral iodized oil vs. placebo. | 24 wk | None, only UIC. | n=159 in I group and n= 151 in placebo group. | After baseline testing the children were randomly assigned to receive 400 mcg oral I as iodized poppy seed oil (Lipiodol) or a sunflower oil (placebo). The capsules were swallowed with water under direct supervision. | 6 children moved and did not complete the cognitive retesting (4 in I group, 2 in placebo group) (4%). Thyroid function tests was not measured at follow up in 12% of the children because they refused blood sampling. | I group: UIC increased from 42 (0–186) to 172 (18–724) µg/L, Thyroid volume reduced from 5.9 (2.6–12.5) to 5.0 (2.4–9.7) mL, TSH unchanged 0.8 (0.3–2.5) and 0.7 (2.4–2.6), TT4 increased from 76 ±17 to 106±18 nmol/L. Placebo group: UIC unchanged 44 (0–215) and 49 (3–221), thyroid volume unchanged 6.2 (2.1–16.8) and 6.3 (2.6–16.0) mL, TSH unchanged 0.9 (0.4–2.6) 0.8 (0.2–7.7), TT4 unchanged 75 ±17 and 81 ±19 nmol/L. I group signifies improved performance on 4 of 7 tests (mean adjusted treatment effect (95% CI)): Rapid target marking 2.8 (1.6–4.0), symbol search 2.8 (1.9–3.6), rapid object naming 4.5 (2.3–6.6), and Raven's Coloured Progressive Matrices 4.7 (3.8–5.8). | Baseline difference between groups, sex, and school. | B Study from an iodine-deficient area in Albania. Might not be relevant for the Nordic countries. |
van den Briel et al., 2000. West Africa (25) | RCT, double blind. Data treated as cohort study. | Children 6–12 years from four primary schools n=211 (approx. 85% boys). | Height, weight, blood (TSH, serum ferritin, Tg, free T4), urine. Mental test battery: closure, concentration, exclusion, fluency, mazes, hand movements, colored progressive matrices. Two psychomotor tests–pegboard and ball throwing. | Iodine supplement (1 mL iodized oil 540 g I/L) or placebo. | Baseline measurements in Oct and Nov 1995. repeated in Oct and Nov 1996. | None, only UIC. | Improved group (n=128), unchanged group (n=68). | As the population began to have access to iodized salt during the intervention period, the study population was split post hoc on the basis of UIC into group with improved iodine status and a group with unchanged iodine status (i.e. status changed from severe iodine deficiency to moderate, from severe to normal-mild, or from moderate to normal-mild). | 13 children left school or moved and 2 children could not be located during urine collection. Drop-out 7%. | Children with increased UIC from baseline to endpoint (improved iodine status) had significantly greater increase in performance on the combination of mental tests than did the group with no change in UIC (0.12±0.06, p=01044). | Both groups consisted of supplemented and non-supplemented children, proportions not different. Also comparable in HB concentration, anthropometric and socioeconomic indexes and initial scores on the mental tests. | B Study includes schoolchildren in Benin and reflects not Nordic countries. The results suggest a “catch up” effects in terms of mental performance after iodine supplementation. |
Reference, details, first author year, country | Study design | Population, subject | Outcome measures | Intervention/exposure | Time between baseline exposure and outcome assessment | No. of subjects analyzed | Follow-up period, drop-out rate | Results | Confounders adjusted for | Study quality and relevance, Comments A-C |
Ayturk et al., 2009. Turkey (32) | Case–control study. | New patients (18–74 years) with metabolic syndrome (n=278) living in a mild-to moderate iodine deficiency area, who attended for regular follow-up. 261 euthyroid control subjects without known thyroid disease recruited from patients admitting to family outpatient clinic. Matched according to age, gender, and smoking. | TSH, thyroid volume and nodule prevalence. | n=539; n=278 in the MetS group (33.1% male) and n=261 in the control group (30.7% male) | TSH was significantly correlated with the presence of MetS. In a multiple linear regression analysis, independent predictors of thyroid volume (mL) were (B, 95% CI); waist circumference (cm) 0.335 (0.089–0.161), triglycerides (mg/dL) 0.136 (0.003–0.016), and insulin resistance 0.143 (0.512–2.731). | BMI, smoking, fat-mass | B No information on iodine nutrition (neither urine iodine nor iodine intake). Patients with MetS have signifies increased thyroid volume and nodule prevalence. Insulin resistance is suggested as an independent risk factor for nodule formation in an iodine-deficient environment. | |||
Hoption Cann et al., 2007. USA (33) | Cohort study. | NHEFS, 25–74 years, n=5811 males. Excluded due to lack of urinary iodine at baseline (n=1577), leaving 4234 men for analysis. Mean age at examination 52.7 years, 16.5% non-white. Tertiles of Iodine/Creatinine categories (<201 n=1452, 201–345 n=1554, >345 n=1228, referred to as low, moderate and high levels). | Prostate cancer incidence. | Iodine status (UIC and UI/Cr ratio). Spot samples. | Baseline in 1971 and 1975, Follow up in 1982–1984, 1986, 1987 and 1992). | n=4234 subjects, n=197 cases. | 7–21 years Drop-out 10%. | Moderate I/Cr associated with a borderline increase risk of prostate cancer relative to low levels (HR = 1.33 (95% CI 1.00–1.78). NS in the multivariate model (HR = 1.31 (0.98–1.75)). High levels was associated with a reduced risk of prostate cancer, HR= 0.71 (0.51–0.99) but NS in the multivariate model (HR = 0.75 (0.53–1.05)). Reported history of thyroid disease was associated with greater than twofold increased risk, HR = 2.34 (1.24–4.43), remained significant after adjustment (HR = 2.16 (1.13–4.14) | Age, race, marital status, family income, alcohol consumption at baseline, region | B The role of iodine remains speculative, a role of thyroid disease and/or factors contributing to thyroid disease as a risk factor for prostate carcinogenesis warrants additional investigation. |
Reference, details, first author year, country | Study design | Population, subject | Outcome measures | Intervention/exposure | Time between baseline exposure and outcome assessment | Dietary assessment method | No. of subjects analyzed | Intervention | Follow-up period, drop-out rate | Results | Confounders adjusted for | Study quality and relevance, Comments A-C |
Zimmermannet al., 2005. Multiethnic (North and South America, Central Europe, Eastern Mediterranean, Africa and the Western Pacific) (34) | Cross-sectional. | 6–12 year children primary schools whose pupils were of middle-to-low socioeconomic status. | Thyroid volume (by ultrasound measurement). | Iodine intake assessed by UIC in spot urine samples. | None, only UI. | n=3319. (n=534 from Switzerland, n=526 from Bahrain, n=591 from South Africa, n=524 from Peru, n=562 from Chelsea MA, n=302 from central Japan, n=280 from coastal Japan). | 31% of children had UIC> 300 mcg/L and 11% > 500 mcg/L. UIC of 300–500 mcg/L not associated with increased Tvol. Tvol started to increase at a UIC ≈ 500 mcg/L. | Age, sex and body surface area (BSA). | B The authors don‘t rule out adverse effects of UIC in the range of 300–500 mcg/day not detected in this study. |